Repurposing Drugs Guided by Tissue Slice Screening in Cancer Patients Without Standard Treatment

The goal of this clinical trial is to learn whether a new laboratory method called OPTin can help doctors select the most effective, personalized cancer therapies for patients with advanced or treatment-resistant tumors. The study will also learn about the safety and feasibility of using OPTin to guide treatment decisions across different cancer types.

The main questions it aims to answer are:

Does OPTin accurately identify which drugs or drug combinations work best for each patient's tumor?

Does OPTin-guided therapy improve tumor response or remission rates when the patients don't have any standard treatment selection?

Study Design:

Researchers will collect treatment outcomes in patients whose therapy is chosen based on OPTin results or not in cancer patients without standard treatment.

Participants will:

Provide a small tumor tissue sample for OPTin testing.

Receive either a drug or drug combination identified by OPTin, or a physician's decision treatment.

Visit the clinic regularly for imaging, blood tests, and side-effect monitoring.

Be followed for several months to evaluate treatment response and overall health.

Example Case:

In a previous proof-of-concept study, OPTin screening in a patient with advanced hypopharyngeal carcinoma identified venetoclax as effective for the primary tumor and lenvatinib as a sensitizing agent for metastasis. Combination therapy led to near-complete remission and a significant drop in serum AFP levels.

These results support evaluating OPTin in a prospective clinical trial involving diverse cancer types to confirm its usefulness in guiding precision oncology.